1. A phase I study of the PD-L1 inhibitor, durvalumab, in combination with a PARP inhibitor, olaparib, and a VEGFR1–3 inhibitor, cediranib, in recurrent women's cancers with biomarker analyses. Issue 1 (25th July 2019) Authors: Zimmer, Alexandra S.; Nichols, Erin; Cimino-Mathews, Ashley; Peer, Cody; Cao, Liang; Lee, Min-Jung; Kohn, Elise C.; Annunziata, Christina M.; Lipkowitz, Stanley; Trepel, Jane B.; Sharma, Rajni; Mikkilineni, Lekha; Gatti-Mays, Margaret; Figg, William D.; Houston, Nicole D.; Lee, Jung-Min Journal: Journal for immunotherapy of cancer Issue: Volume 7:Issue 1(2019) Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗